semaglutide vs tirzepatide pcos vs. for 📣 Today in @Reuters, Truveta

In a randomized, placebo-controlled study, pemvidutide, a dual GLP-1/GCG receptor agonist, significantly decreased liver fat content by up to 68.5% after 12 weeks of treatment, accompanied by reductions in hepatic inflammation markers and body weight, highlighting the potential of dual receptor agonists to modify MASLD pathophysiology (47)

There currently is no cure or set treatment for gastroparesis

Slower weight loss allows the skin to gradually adjust, giving collagen and elastin networks time to partially reorganize as the body shrinks

The characteristics of the 13 studied were described in Table 1

We offer maintenance plans with nutritional coaching